About: Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $0.31 (-1.10%)
TPST NASDAQ Tempest Therapeutics Inc
Tempest Therapeutics Inc share price
Atividade de preço de TPST
Último preço
$ 0,310
Variação (24h)
-0,00 USD (1,10%)
Volume
302.51K
Volume (média 4 sem.)
-
Abertura
$ 0,31
Variação do dia
$ 0,29 - $ 0,32
Fechamento anterior
$ 0,31
Último negócio
19 Nov, 9:00 pm GMT+0
Atrasado
19 Nov, 9:00 pm GMT+0
TPST price performance
Atrasado
19 Nov, 9:00 pm GMT+0
TPST details
quote.marketSignals